Psychiatr. pro Praxi, 2005; 5: 220-224

SECOND GENERATION ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DISORDER

MUDr. Ivan Tůma CSc
Psychiatrická klinika LF UK a FN Hradec Králové

The second generation antipsychotics have expanded the treatment armamentarium for bipolar disorder. Most of the second generation antipsychotic drugs have been found to be effective in clinical controlled trials as monotherapy in bipolar mania or as an add-on treatment with mood stabilizers. The second generation antipsychotic drugs possess a number of advantages, including significantly less extrapyramidal symptoms, diminished risk of tardive dyskinesia, lack of increase in serum prolactin levels (with the exception of risperidone), and improvement in cognition. Data indicate that second generation antipsychotics can serve as adjunctive as well as alternative agents in the treatment of manic states. AP II have also demonstrated beneficial effects in the treatment of bipolar depression and during the maintenance phase of the treatment.

Keywords: Key words: bipolar disorder, mania, depression, second generation antipsychotics.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tůma I. SECOND GENERATION ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DISORDER. Psychiatr. praxi. 2005;9(5):220-224.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angst J, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181. Go to original source... Go to PubMed...
    2. Baker RW, Brown E, Tohen M, Schuh L, Trzepacz PT. Dysphoric Mania: A controlled study of the benefits of olanzapine combined with valproate or lithium. NIMH - NCDEU 43rd Annual Meeting 2003, poster session: nečíslováno.
    3. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE Jr, McElroy SL, Sachs G, Vieta E, Welge JA, Yatham LN, Zarate CA Jr, Baker RW, Tohen M. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol. 2003 Aug; 23(4): 370-376. Go to original source... Go to PubMed...
    4. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double blind randomised controlled trial. Int Clin Psychopharmacology 1999; 14: 339-343. Go to original source... Go to PubMed...
    5. Bowden CL Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 2001; 52: 51-55. Go to PubMed...
    6. Bowden CL Treatment Options for bipolar depression. J Clin Psychiatry 2005; 66(suppl 1): 3-6.
    7. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology 2003; 166: 315-332. Go to original source... Go to PubMed...
    8. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. Am J Psychiatry. 2005 Jul; 162(7): 1351-1360. Go to original source... Go to PubMed...
    9. Češková E. Mánie a jejich léčba. Čs. Psychiatrie 1994; 90(3): 131-141.
    10. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002 Oct; 41(10): 1216-1223. Go to original source... Go to PubMed...
    11. Goodwin GM. Evidence-based guidelines for treating bipolar disorders: recommendation from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149-173. Go to original source... Go to PubMed...
    12. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ. The World Federation of Societies of Biological Psychiatry, WFSBP guidelines for the biological treatment of bipolar disorders: Part II, Treatment of Mania. World J Biol Psychiatry 2003; 4: 5-13. Go to original source... Go to PubMed...
    13. Herman E, Grof P, Hovorka J, Praško J, Doubek P. Bipolární porucha. In Seifertová D, Praško J, Höschl C. Postupy v léčbě psychických poruch (Eds) Academia Medica Pragensis, Medical Tribune CZ 2004: 94-126.
    14. Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004 Jun; 161(6): 1057-1065. Go to original source... Go to PubMed...
    15. Hirschfeld RMA, et al. Treatment of patients with bipolar disorder. In: American Psychiatric Association Prectice Guidelines for the treatment of psychiatric disorders. Compedium 2004: 525-612.
    16. Höschl C. Afektivní poruchy. In: Höschl C, Libiger J, Švestka J, (Eds). Psychiatrie. Tigis 2002: 446-447.
    17. Hrdlička M, Bareš M, Propper L. Postavení neuroleptik v léčbě bipolární poruchy. Čs. Psychiat 1999; 95(7): 453-461.
    18. Chou CYJ, Tůma I, Sweeney E. Treatment Approaches for Acute Mania. Psychiatric Quarterly 64, 1993; 4: 331-344. Go to original source... Go to PubMed...
    19. Chou JCY, Czobor P, Charles O, Tuma I, Winsberg B, Allen MH, Trujillo M, Volavka J. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol 1999; 19: 500-505. Go to original source... Go to PubMed...
    20. Jones M, Huziar K. Quetiapine monotherapy for mania associated with bipolar disorder. Int J Psychiatry Clin Pract 2003; 7: 310-311, Abs P14.
    21. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.Am J Psychiatry. 2003 Apr; 160(4): 741-748. Go to original source... Go to PubMed...
    22. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001 Aug; 21(4): 389-97. Go to original source... Go to PubMed...
    23. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in Acute Bipolar Mania: A 21-Day Randomized, Double-Blind, Placebo-Controlled Replication Trial. J Clin Psychopharmacol. 2005 Aug; 25(4): 301-310. Go to original source... Go to PubMed...
    24. Raymond R, Bourin M, Auby P, Marcus R, McQuade RD, Carson WH, Iwamoto T. Aripiprazole vs. haloperidol for maintained treatment effects in patients with acute mania. NIMH - 43rd Annual NCDEU Meeting 2003: Poster Session I: nečíslováno. Go to original source...
    25. Sachs et. al. APA Expert Guideline Series. 2000.
    26. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002 Jul; 159(7): 1146-1154. Go to original source... Go to PubMed...
    27. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs DL, Breier A. Olanzapine in the acute treatment of bipolar I disorders with a history of rapid cycling. J Affect Dis 2003;73:155-161. Go to original source... Go to PubMed...
    28. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21: 176-180. Go to PubMed...
    29. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005 Jan; 15(1): 75-84. Go to original source... Go to PubMed...
    30. Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RM, Keck PE Jr, Sachs GS, Crismon ML, Toprac MG, Shon SP; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry. 2002 Apr; 63(4): 288-299. Go to original source... Go to PubMed...
    31. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC. The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder J Clin. Psychiatry 2005; 66: 870-886. Go to original source... Go to PubMed...
    32. Švestka J. Aripiprazol - antipsychotikum nové generace s jen parciální agonizací dopaminových D2/D3 a serotoninových 5-HT1A receptorů. Psychiatrie 2003; 7(4):279-289.
    33. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa R, Daniel DG, Petty F, Centorrino F, Wang R, Grundy S, Graeney MG, Jacobs TG, David S, Toma V. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156: 702-709. Go to original source... Go to PubMed...
    34. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000; 57: 841-849. Go to original source... Go to PubMed...
    35. Tohen M, Zhang F, Feldman PD, Evans AR, Breier A. Olanzapine versus haloperidol in the treatment of acute mania. Bipolar Disord 2001a; 3: 61.
    36. Tohen M, Baker RW, Milton DR, Risser RC, Gilmore JA, Davis AR, Richey AL. Olanzapine versus divalproex sodium for the treatment of acute mania. Bipolar Disord 2001b; 3: 60. Go to original source...
    37. Tohen M, Chengappa KNR, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CHL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002a; 59: 62-69. Go to original source... Go to PubMed...
    38. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002b Jun; 159(6): 1011-7. Go to original source... Go to PubMed...
    39. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003 Dec;60(12):1218-26. Go to original source... Go to PubMed...
    40. Tohen M, Vieta E, Calabrese J. et al. Efficacy of olanzapine and olanzapine fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088. Go to original source... Go to PubMed...
    41. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005 Jul; 162(7): 1281-1290. Go to original source... Go to PubMed...
    42. Tůma I, Chou JCY. Antipsychotika druhé generace v léčbě mánie. Psychiatrie 2004; 8(1): 54-61.
    43. Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martinez G, Fernandez A, Colom F, Martinez-Aran A, Torrent C. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818-825. Go to original source... Go to PubMed...
    44. Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernandez A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord. 2002 Oct; 72(1): 15-9. Go to original source... Go to PubMed...
    45. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003 Apr; 182: 369. Go to original source... Go to PubMed...
    46. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002 Dec; 63(12): 1148-55. Go to original source... Go to PubMed...
    47. Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411-417.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.